Synthesis and antifungal activity ofpradimicin analogs modified on the aglycone part is described. Uponmodification studies at various sites of the aglycone part using pradimicin A(PRMA), C-l l position was found to be the sole site to be modified without loosing antifungal activity. Further modification studies at C-l 1 position were carried out with 1 1-OH derivative of pradimicin Tl (PRM Tl) because of its easy availability. Amongthe compounds prepared, 1 1-demethoxy derivative of PRMA (12) Thesecompounds werereported to be as active as PRMA. This encouraged us to modify the aglycone part ofPRMs, specifically at C-l 1 position to obtain a compoundmore potent than PRMA. Herein, we describe the synthesis and in vitro antifungal activity of pradimicin derivatives modified on the aglycone part ofPRMA and Tl. SEPT. 1993 Various kinds of reactions were performed to introduce a functional group on the aglycone part of PRMA and the results are summarizedin Scheme1.
Phenolic-O-methylations of 4'-NBoc derivative of PRMA (B) with Mel-K2CO3in DMSOor Me2SO4-NaOH in dioxane in the presence of phase transfer catalyst, followed by deprotections and purification by C18 reversed phase column chromatography afforded 9-OMe (1) and 1-OMe (2) derivatives of PRMA in 4.7 and 1.7% yield, respectively. The structure of compound 1 was definitely determined by the strong NOEobserved between 9-OMeand 10-H. In compound 2, the unusually high field resonance of 1-OMeprotons ((5 3.55, presumably due to the anisotropic effect of non-coplanar aromatic ring system) and lower field shift of 4-H (S 7.34, the para position of C-l) in *H NMR,along with the characteristic shift in UVabsorption (>imax 523 nm) were observed. These data strongly indicated the methylation site of compound2 to be the 1-OHposition of PRMA. Similar spectroscopic data were reported in the 1-0-glucoside derivative of PRML. 4) Halogenation of PRMA with pyridinium bromide perbromide (Py-HBr3) or I2 -Nal -NaOH gave different two types of substitution products, 4-bromo (3) and 10-iodo (4) derivatives ofPRM A, respectively, whose structures were determined by comparative NMR analysis of the aromatic protons as shown in Scheme1. These results suggested that substitution reactions such as halogenation occurred at 4-position under acidic conditions and at 10-position under alkaline conditions. This observation was supported by the fact of introduction of nitro group at 4-position (compound 6) under acidic condition and at 10-position (compound 8) by basic Mannich reaction described below. 10-Iodo derivative 4 was further converted to the corresponding 10-carboxy derivative 5 by lithiation with tert-BuLi, followed by treatment with carbon dioxide.
Treatment of PRMA with NOBF46)in MeCNafforded 4-nitro derivative 6 in an excellent yield. Although the hydrogenolysis of 6 on Pd-C under hydrogen atmosphere did not proceed at all, reduction with NaSH in MeOHwas found to smoothly afford the desired 4-amino derivative 7 in 58% yield. All C-4 substituted derivatives (3, 6 and 7) were found to have a different conformation of 5,6-dihydro-ring from that ofPRM A, byjudging from coupling constants (J5 6=ca. 3 Hz for 3, 6 and 7 and J-ca. 10Hz for PRMA). This was also supported by the alteration of CDspectra between 3 [/lextreme (MeOH)nm Ode) 210 (-26. The Mannich reaction of PRMA with Me2NH-HCHOat 90°C overnight unexpectedly afforded 4/-NMe2-10-CH2N+Me3derivative 8 in 54% yield, which might be formed via the normal 10-CH2NMe2 Mannich type derivative by over iV-methylation with HCHOat an elevated temperature. The structure of 8 was also confirmed by the formation of the corresponding 10-Me derivative 9 by the hydrogenolysis of 10-trimethyl ammoniumgroup with H2 -Pd-C.
Reduction ofquinone group ofPRMA with zinc-powder in AcOHgave 1 3-deoxo derivative 10, whose structure was confirmed by NOEobserved between 12-H and newly appeared 13-methylene protons (S 4. 18) Finally, de-O-methylation at C-l l position of PRMA was successfully performed using Lil-collidine at reflux temperature to afford the ll-OH derivative of PRMA (II)1" in 9.4% yield. When an other arylether cleavage reagent8) such as TMS-I, BBr3, BF3-Et2O, PhSNa or EtSNa was used, the reaction did not proceed at all or resulted in decompositions. ll-Hydroxy derivative ll was deoxygenated by reduction of the corresponding 1 1-O-triflate intermediate C (Scheme 1) with HCOOH-NEt3 in the presence of Pd(0) catalyst to afford the desired ll-deoxy derivative of PRMA (12) in 25% yield.
Modification at C-ll Position of PRMTl
The in vitro antifungal activity of a series of the aglycone modified derivatives of PRMA(details see below) indicated that the C-l 1 position was the only site to be modified without loosing activity. Thus we carried out further modifications at C-l 1 position starting from 1 1-hydroxy pradimicin Tl, because of its easy availability from PRMTl by 1 1-0-dexylosylation.
The modification results are summarized in Scheme 2.
1 1-Hydroxy PRMTl methyl ester (D) was treated with an appropriate (substituted)alkyl halide in
DMSOin the presence of K2CO3to afford ll-6>-(substituted)alkyl derivatives of PRMTl (13-17) in 28~66% yield, after deblocking and purification by C18 column chromatography. The alkylation site of the products was confirmed to be at 1 1-OH position by NOEobserved between 1 1-O-methylene protons and 10-/12-protons.
ll-Deoxy derivative of PRMTl (18) was also prepared by the same procedure as described in the preparation of 12 via the corresponding 1 1-O-triflate derivative (E). Treatments of compound E with Me2NHin DMFgave l l-NMe2 derivative (19) and with Bu3SnCN in the presence of Pd(0) catalyst gave 1 1-CN (20) and 1 1-CONH2 (21) derivatives after deblocking with 1 n NaOH.
Antifungal Activity The in vitro antifungal activity of the aglycone modified derivatives of pradimicins was determined by the agar dilution method on yeast morphology agar containing 1/15 m phosphate buffer (pH 7.0) and the results are summarizedin Table 1 .
Amongthe derivatives modified on the aglycone part of PRMA, most of the compounds (1, 3-10) obtained by the modifications at C-4, 9, 10 and 13 positions, were found to be completely inactive against all fungi tested. It has been noted that compounds (3, 6 and 7 and 7-hydroxy PRMA7)), having different conformation from that of PRMA showed no antifungal activity. Although the 1-OMe derivative (2) showed apparently decreased activity, 1 1-0-demethyl (ll) and 1 1-demethoxy (12) derivatives showed The same compoundll was recently isolated by fermentation in our laboratory and designated pradimicin H. SEPT. 1993 significant activity comparable to that of PRMA. This indicated that the substituents on the aglycone of PRMA are strictly required to be as they are to reveal antifungal activity except for C-l l position. In a series of the C-l 1 modified derivatives ofPRM Tl, 1 1-OEt (13) and 1 1-OCH2CH2F(14) derivatives were found to be more active than the corresponding ll-OH derivative and are as active as PRMA. Although the 1 1-OCH2COOH(16) and 1 1-OCH2CONH2(17) derivatives ofPRM Tl were nearly inactive, the C-ll directly substituted ll-CN (20) and ll-CONH2 (21) derivatives showed fairly good activity. ll-Deoxy derivative of PRMTl (18) also showed excellent level of activity as in the case of PRMA, except against Aspergillus fumigatus.
Experimental
MPswere determined on a Yanagimoto micro hot-stage apparatus and are uncorrected. IR spectra (KBr) were measured on a JASCO IR Report-100 spectrometer and UV spectra (in 0.01 n NaOH) on a Shimadzu UV-260 spectrometer.
XHNMRspectra (in DMSO-d6) were recorded on a JEOL GX-400 (400 MHz)and mass spectra on a JEOLJMS-AX505H mass spectrometer. CDspectra were measured in MeOHon a JASCOJ-600 spectrometer. 
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9-O-Methyl-PRM
A (1) To a solution of compound B (300mg, 0.32mmol) in dry DMSO(10ml) were added K2CO3 (440mg, 3.2mmol) and Mel (0.40ml, 6.4mmol) and the mixture was stirred at room temperature for 5 days. After being poured into water (100ml), the mixture was extracted with EtOAc (3 x 100ml). The combined extracts were washed with brine, dried over Na2SO4and evaporated. The residue was chromatographed on a silica gel (Wako-gel C-200, 150g) by eluting with CH2C12-MeOH=20:1~3: 1 to give a fraction (72mg), showing Rf=0.22 on TLC (Kieselgel 60 F254, CH2C12 -MeOH=20: 1). The compound obtained above in MeOH(5 ml) was treated with 1 n NaOH(0.1 ml) at room temperature for 30minutes, neutralized with 1 n HC1to pH 5.0 and evaporated to dryness. The residue was then treated with trifluoroacetic acid (2ml) at room temperature for 5 minutes and evaporated in vacuo below 30°C. The residue was purified on a C18 column (Prep C18, 55~105/mi, Waters, 50ml), which was washed with water and eluted with 25% acetonitrile (MeCN) -phosphate buffer (pH 3.5). The fractions showing Rt= 3.7minutes on HPLC (SSC-ODS-262, 6 x 100mm, 27.5% MeCN-phosphate buffer (pH 3.5)) were collected, desalted on a C18 column by washing with water and eluting with 50% aq MeCN, evaporated and lyophilized to afford the title compound 1 as red powder (12mg, 4.4% yield from B): MP 210°C; IR v^cm"1 1640, 1590; XH NMR(see also 
1-O-Methyl-PRM A (2)
To a solution of B (370mg, 0.39mmol) in dry dioxane (37ml) were sequentially added Bu4NHSO4 (132mg, 0.39mmol), powdered NaOH (109mg, 2.71 mmol) and Me2SO4 (0.13ml, 1.36mmol) and the mixture was stirred at room temperature overnight and the insoluble matters were removedby filtration and washed with dioxane. The combined filtrate and washings were evaporated and the residual syrup was chromatographed on a silica gel (50 g) by eluting with CH2C12-MeOH= 20 : 1. The fractions containing the product showing Rf=0.73 (TLC, same as above) were evaporated and the residue (159mg) was 
4-Bromo-PRM A (3)
To a solution of PRM A (86mg, O.l mmol) in dry pyridine (2ml) was added pyridinium bromide perbromide (32mg, 0.1 mmol) and the mixture was stirred at room temperature for 30 minutes. To the mixture was added I n HC1 and the mixture was charged on a C18 column (80ml), which was washed with water and eluted with 20% MeCN-buffer (pH 3.5). The desired fractions were collected, concentrated, desalted and lyophilized to give the title compound 
10-Iodo-PRM A (4)
A solution of iodine (2.5 g, 12mmol) and Nal (1.92g, 13.2mmol) in water (20ml) was added dropwise to a stirred solution of PRM A (1.0g, 1.2mmol) in water (100ml) under keeping the pH of the solution between 8.5~9.0 by the addition of 0.1 n NaOH(45ml) and the mixture was stirred at room temperature for 1.5 hours. After being acidified with 1 n HG1 to pH 4, the mixture was desalted by HP-20 column (Diaion, 600ml) and the crude solid of 4 obtained (1. 
10-Carboxy-PRM A (5)
A mixture of 4 (75 mg, 0.078 mmol) and hexamethyldisilazane (10ml) was refluxed for 16 hours and the resulting clear solution was evaporated to dryness. To a solution of the residue in dry THF(10ml) was added tert-BuLi (1.7m solution in pentane, 0.2ml) at -70°C and the mixture was stirred at the same temperature for 2 hours. Carbon dioxide was bubbled to the mixture for 30 minutes and then quenched with I n HC1. The mixture was purified by a C18 column (80ml), eluting with 10-20% MeCN-buffer (pH 3.5). The desired fractions were collected, desalted, concentrated and lyophilized to afford the title compound 5 (5mg, 7. 
4-Nitro-PRM A (6)
To a suspension of PRMA (500mg, 0.57mmol) in MeCN(20ml) was added nitrosonium tetrafluoroborate (NOBF4, 197mg, 1.69mmol) and the mixture was stirred at room temperature for 5 minutes. Insoluble solids were removed by nitration and the filtrate was added to cold 2n NaOH(20ml). After evaporation of the organic solvent, the aqueous residue was acidified with 3n HC1 and chromatographed on a C18 column, which was eluted with 15~20% aq MeCNcontaining 0.001 n HC1. The desired fractions were combined, concentrated and lyophilized to give 398 mg (79%) of 6: MP210°C;
IRv^cm"1 1720, 1620; XHNMR 3 1.19 (3H, d, 
4-Amino-PRM A (7)
A mixture of 6 (200mg, 0.23mmol) and 17% aqueous solution of NaSH (4.5ml) in MeOH(20ml) SEPT. 1993 was heated at 80°C for 6 hours. After evaporation of the organic solvent, the aqueous residue was acidified with 3n HC1 and charged on a C18 column, which was washed with water and then eluted with 10~15% aq MeCNcontaining 0.001 n HC1. The desired fractions were combined, evaporated and lyophilized to afford the title compound 7 (113mg, 58%): MP 170°C; IR v^cm"1 1720, 1620; *H NMR 6 1. 4/-7V,A^-DimethyM 0-trimethylammoniummethyl-PRM A (8) A mixture of PRMA (177mg, 0.20mmol), dimethylamine (50% aq soln, 1.4ml) and formaldehyde (37% aq soln, 2.8ml) in water (1.4ml) was heated at 90°C overnight. After concentration, the residue was dissolved in 3 n HC1 and chromatographed on a C18 column by eluting with 10~20% aq MeCNcontaining 0.001 n HC1. The desired fractions were combined, concentrated and lyophilized to give the title compound 8 -A^-Dimethyl-l O-methyl-PRM A (9) Compound 8 (55mg, 0.06mmol) in a mixture of MeOH(0.5ml) and 1 n HC1 (0.1 ml) was subjected to hydrogenation in the presence of 5% Pd-C (10 mg) under hydrogen atmosphere at room temperature for 1 hour. The catalyst was removed by filtration and the filtrate was evaporated. The residue was chromatographed on a C18 column eluting with 25% aq MeCNcontaining 0.001 n HC1 to afford the title compound9(4.5mg, 9%): MP220oQ IR vmaxcm"1 1720, 1620; XH NMR (5 1.21 (3H, d,.7=6.8Hz, 5'-Me), 1 
13-Deoxo-PRM A (10)
A mixture of PRM A (150mg, 0.18mmol) and zinc-powder (150mg, 0.18mmol) in acetic acid (3ml) was heated under reflux for one hour. After cooling, water (10ml) was added and the mixture was filtered to remove insoluble materials. The filtrate was chromatographed on a C18 column (50ml), which was washed with water and eluted with 30%aq MeCN.The fractions containing the desired product were combined, concentrated and freeze-dried to give 51 mg (35%) of the product 10: MP200°C (dec); IR A mixture of pradimicin A (420mg, 0.5mmol) and anhydrous lithium iodide (1.34g, lOmmol) in collidine (50 ml) was refluxed for 2 hours with stirring, diluted with ether (200 ml) after cooling and filtered. The solid was dissolved in water (100ml) and the solution was acidified with 1 n HC1and charged on a C18 column (400 ml), which was eluted with 25 -30% MeCN-buffer (pH 3.5). The desired fractions showing retention time 4.1 minutes [25% MeCN-buffer (pH 3.5)] were combined, concentrated, desalted and freeze-dried to give 39mg (9.4%) of the title compound ll: MP >200°C; IR v^cm"1 1720, 1610; *H -JV-Cbz-l l -O-trifluoromethanesulfonyl-PRM A Methyl Ester (C) A mixture of4'-iV-Cbz-l 1 -hydroxy-PRM A methyl ester [1 7 mg, 0.01 8 mmol, prepared from compound ll by the conventional method reported before4)], AT-phenyltrifluoromethanesulfonimide (9.4mg, 0.026 mmol) and Af,iV-dimethylammopyridine (3.2mg, 0.026 mmol) in dry pyridine (1.7 ml) was stirred at room temperature for one hour. The mixture was diluted with pH 3.5 phosphate buffer (20 ml) and charged To a solution of the triflate C obtained above (23 mg, 0.02 mmol) in dry DMF(2 ml) were sequentially added palladium acetate (9 mg, 0.04 mmol), triphenylphosphine (21 mg, 0.08 mmol), triethylamine (28 /4 0.2mmol) and 98% formic acid (8 jul, 0.21 mmol) and the mixture was stirred at room temperature for 4 hours. The mixture was diluted with pH 3.5 phosphate buffer and charged on a C18 column (80 ml), which was eluted with 40~50%MeCN-buffer (pH 3.5). The desired fractions were combined, concentrated, desalted and freeze-dried to give 14mg (73%) of the 1 1-deoxy derivative of compound C: MP>200°C; A mixture of the compound obtained above (14mg, 0.015mmol) and 10%Pd-C (lOmg) in a mixture of MeOH(3 ml), water (1 ml) and AcOH(1 ml) was hydrogenated at room temperature for 3 hours under hydrogen atmosphere. The catalyst was removedby filtration and the filtrate was charged on a C18column (80ml), which was washed with water and eluted with 75%aq dioxane. The desired fractions were concentrated, diluted with MeOH(5ml) and treated with I n NaOH(l ml). The mixture was stirred at room temperature for 30 minutes and adjusted to pH 6 with 1 n HC1 and purified by a C18 column (80ml), eluting with 30% MeCN-buffer (pH 3.5). The desired fractions were combined, concentrated, desalted and freeze-dried to give 4mg (34%) of the title compound 12: MP >200°C; *H NMRS Ethyl bromide (10/4 0.14mmol) was added to a mixture of compound D (25mg, 0.030mmol) and K2CO3 (8 mg, 0.058 mmol) in DMSO(0.3 ml) and the mixture was stirred overnight at room temperature. To the mixture was added 1 n NaOH(3 ml) and the mixture was stirred overnight at room temperature. After acidification with dil HC1,the mixture was chromatographed on a C18column, which was washed with water and then eluted with 10~15% aq MeCN.The fractions containing the desired product were combined, concentrated in vacuo and freeze-dried to give 13 mg (52%) of the product 13: MP200~210°C (dec); XH NMR (see also By the similar procedures described above, treatment of the ester D with l-bromo-2-fluoroethane, allyl bromide, ethyl bromoacetate or iodoacetamide, followed by deblocking and purification afforded compounds 14~17, respectively. 
